Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Cited by (406)

Items 101–200 of 406

1. Therapeutic Inducers of Apoptosis in Ovarian Cancer
   Mudra Binju, Monica Angelica Amaya-Padilla, Graeme Wan, Hendra Gunosewoyo, Yohan Suryo Rahmanto, Yu Yu · 2019 · Cancers
2. Targeting Mutant p53 in Human Tumors
   Brian David Lehmann, Jennifer A. Pietenpol · 2012 · Journal of Clinical Oncology
3. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
   Xiangyan Li, Boyang Jason Wu, Leland W.K. Chung, Wen‐Chin Huang · 2015 · Oncotarget
4. TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
   Matteo Molica, Carla Mazzone, Pasquale Niscola, Paolo de Fabritiis · 2021 · Frontiers in Oncology
5. Novel targets and interaction partners of mutant p53 Gain-Of-Function
   Lydia Aschauer, Patricia A. J. Muller · 2016 · Biochemical Society Transactions
6. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
   Naoise C. Synnott, Matthias R. Bauer, Stephen F. Madden, Alyson M. Murray, Rut W. Klinger, Norma O’Donovan, Darran P. O’Connor, William M. Gallagher, John Paul Crown, Alan Roy Fersht et al. · 2017 · Cancer Letters
7. Targeting Casein Kinase 1 (CK1) in Hematological Cancers
   Pavlína Janovská, Emmanuel Normant, Hari P. Miskin, Vı́tězslav Bryja · 2020 · International Journal of Molecular Sciences
8. A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage
   John M. Findlay, Mark Ross Middleton, Ian P.M. Tomlinson · 2014 · Annals of Oncology
9. Oncogenic Intra-p53 Family Member Interactions in Human Cancers
   Maria A. Ferraiuolo, Silvia Di Agostino, Giovanni Blandino, Sabrina Strano · 2016 · Frontiers in Oncology
10. Targeting mutant p53 in cancer: a long road to precision therapy
    Fiamma Mantovani, Dawid Walerych, Giannino Del Sal · 2016 · FEBS Journal
11. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines
    Patrícia Izetti, Agnès H. Hautefeuille, Ana Lúcia Abujamra, Caroline Brunetto de Farias, Juliana Giacomazzi, Bárbara Alemar, Guido Lenz, Rafael Roesler, Gilberto Schwartsmann, Alessandro Bersch Osvaldt et al. · 2014 · Investigational New Drugs
12. Cell death pathologies: targeting death pathways and the immune system for cancer therapy
    Francesca Pentimalli, Sandro Grelli, Nicola Di Daniele, Gerry Melino, Ivano Amelio · 2018 · Genes and Immunity
13. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer
    Fransson, Åsa, Glaessgen, Daria, Alfredsson, Jessica, Wiman, Klas G., Bajalica-Lagercrantz, Svetlana, Mohell, Nina · 2016 · Journal of Ovarian Research
14. Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
    YEE-LIN VOON, Pooi‐Fong Wong, Alan Soo Beng Khoo · 2017 · Mini-Reviews in Medicinal Chemistry
15. Small molecule compounds targeting the p53 pathway: are we finally making progress?
    Xin Yu, Sumana Narayanan, Alexei Vázquez, Darren R. Carpizo · 2014 · APOPTOSIS
16. The role of the MDM2/p53 axis in antitumor immune responses
    Tilman Brummer, Robert Zeiser · 2023 · Blood
17. A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications
    Mengxiong Wang, Laura Donatella Attardi · 2021 · Annual Review of Pathology Mechanisms of Disease
18. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations
    Yuheng Hong, Tianyuan Ren, Xiaoxuan Wang, Xia Liu, Yue Fei, Shen Meng, Xu Han, Cong Sun, Hongru Shen, Lanfang Li et al. · 2022 · Leukemia
19. APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines
    Christophe Deben, Filip Lardon, An Wouters, Ken Op de Beeck, Jolien Van den Bossche, Julie Jacobs, Nele Van Der Steen, Marc Peeters, Christian D. Rolfo, Vanessa Deschoolmeester et al. · 2016 · Cancer Letters
20. When the guardian sleeps: Reactivation of the p53 pathway in cancer
    Olaf Merkel, Ninon Taylor, Nicole Prutsch, Philipp Bernhard Staber, Richard Moriggl, Suzanne Dawn Turner, Lukas Kenner · 2017 · Mutation Research/Reviews in Mutation Research
21. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems
    Daiha Shin, Eun Hye Kim, Jaewang Lee, Jong‐Lyel Roh · 2017 · Redox Biology
22. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
    Yan Stein, Ronit Aloni-Grinstein, Varda Rotter · 2020 · Carcinogenesis
23. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
    Huaxin Song, Jiale Wu, Yigang Tang, Yuting Dai, Xinrong Xiang, Ya Li, Lili Wu, Jiaqi Wu, Ying Liang, Yangfei Xing et al. · 2023 · Science Translational Medicine
24. p53 as an intervention target for cancer and aging
    Paul Hasty, Barbara A. Christy · 2013 · Pathobiology of Aging & Age-related Diseases
25. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
    Yi Miao, Leonard Jeffrey Medeiros, Zijun Yidan Xu-Monette, Jianyong Li, Ken H. Young · 2019 · Frontiers in Oncology
26. Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
    Sayantanee Dutta, Gudrun Pregartner, Frank G. Rücker, Ellen Heitzer, Armin Zebisch, Lars Bullinger, Andrea Berghold, Konstanze Döhner, Heinz Sill · 2020 · Cancers
27. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
    Salih Demir, Elena Boldrin, Qian Sun, Stephanie Hampp, Eugen Tausch, Cornelia Eckert, Martin Ebinger, Rupert Handgretinger, Geertruy te Kronnie, Lisa Wiesmüller et al. · 2019 · Haematologica
28. Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse
    Fan Yang, Samuel W. Brady, Chao Shu Tang, Huiying Sun, Lijuan Du, Malwine Barz, Xiaotu Ma, Yao Chen, Houshun Fang, Xiaomeng Li et al. · 2021 · Nature Cancer
29. p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
    Phaik Ju Teoh, Wee Joo Chng · 2014 · BioMed Research International
30. Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
    Paola Menichini, Paola Monti, Andrea Speciale, Giovanna Cutrona, Serena Matis, Franco Fais, Elisa Taìana, Antonino Neri, Riccardo Bomben, Massimo Gentile et al. · 2021 · Cells
31. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers
    Per Eystein Lønning, Stian Knappskog · 2013 · Oncogene
32. Pharmacological activation of wild-type p53 in the therapy of leukemia
    Kensuke Kojima, Jo Ishizawa, Michael Andreeff · 2016 · Experimental Hematology
33. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis
    James Andrew McCubrey, Kvin Lertpiriyapong, Timothy Louis Fitzgerald, Alberto Maria Martelli, Lucio Cocco, Dariusz Rakus, Agnieszka Gizak, Massimo Libra, Melchiorre Cervello, Guiseppe Montalto et al. · 2016 · Advances in Biological Regulation
34. TP53 mutations in head and neck cancer
    Cherie‐Ann O. Nathan, Alok R. Khandelwal, Gregory T. Wolf, Juan Pablo Rodrigo, Antti A. Mäkitie, Nabil F. Saba, Arlene A. Forastiere, Carol Rossier Bradford, Alfio Ferlito · 2022 · Molecular Carcinogenesis
35. Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53‐dependent manner
    Bin Zhang, Xiaoting Shi, Guifang Xu, Wei Kang, Weijie Zhang, Shu Zhang, Yu Qing Cao, Liping Qian, Ping Zhan, Hongli Yan et al. · 2017 · Journal of Cellular and Molecular Medicine
36. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation
    Yoav Shetzer, Alina Molchadsky, Varda Rotter · 2016 · Cold Spring Harbor Perspectives in Medicine
37. Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells
    Ali, Dina, Mohammad, Dara K., Mujahed, Huthayfa, Jonson‐Videsäter, Kerstin, Nore, Beston, Paul, Christer, Lehmann, Sören · 2016 · British Journal of Haematology
38. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
    Xiaolan Li, Jianbiao Zhou, Zit-Liang Chan, Jing-Yuan Chooi, Zhirong Chen, Wee Joo Chng · 2015 · Oncotarget
39. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?
    Michael Joe Duffy, Minhong Tang, Subhasree Rajaram, Shane O’Grady, John Paul Crown · 2022 · Cancers
40. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
    H. Park, Geoffrey Ira Shapiro, Xinyu Gao, Amit Mahipal, Jason Scott Starr, Muhammad Furqan, Parminder Pal Singh, Afzal Ahrorov, Leena Gandhi, Arnab Ghosh et al. · 2022 · ESMO Open
41. p53 and Zinc: A Malleable Relationship
    Jeung‐Hoi Ha, Orjola Prela, Darren R. Carpizo, Stewart N. Loh · 2022 · Frontiers in Molecular Biosciences
42. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
    Xiaoxian Li, Gabriela Oprea‐Ilies, Uma Krishnamurti · 2017 · Archives of Pathology & Laboratory Medicine
43. The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53
    Esha Madan, Taylor M. Parker, Matthias R. Bauer, Alisha Dhiman, Christopher James Pelham, Masaki Nagane, M. Lakshmi Kuppusamy, Matti Holmes, Thomas R. Holmes, Kranti Shaik et al. · 2018 · Journal of Biological Chemistry
44. Molecular genetics of head and neck squamous cell carcinoma
    Esma Saâda-Bouzid, Frédéric Peyrade, Joël Guigay · 2019 · Current Opinion in Oncology
45. Cellular senescence and hematological malignancies: From pathogenesis to therapeutics
    Dingyu Hu, Shunling Yuan, Jing Zhong, Zhaoping Liu, Yanyan Wang, Li Liu, Junjun Li, Feng Wen, Jing Liu, Ji Zhang · 2021 · Pharmacology & Therapeutics
46. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
    Sangeeta Kumari, Vikas Sharma, Rahul Tiwari, Jay Prakash Maurya, Bharat Bhusan Subudhi, Dhirodatta Senapati · 2022 · European Journal of Pharmacology
47. APR-246/PRIMA-1 MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations
    Jinfeng Shen, Ellen H. J. van den Bogaard, Evelyn N. Kouwenhoven, Vladimir J.N. Bykov, Tuula Rinne, Qiang Zhang, Geuranne S. Tjabringa, Christian Gilissen, Simon J. van Heeringen, Joost Schalkwijk et al. · 2013 · Proceedings of the National Academy of Sciences
48. Markov state models and NMR uncover an overlooked allosteric loop in p53
    Emília P. Barros, Ö. Demir, Jenaro Soto, Melanie J. Cocco, R. Amaro · 2020 · bioRxiv
49. Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
    Katarzyna A. Roszkowska, Aleksandra Piecuch, Maria Sady, Zdzisław Gajewski, Sylwia Flis · 2022 · International Journal of Molecular Sciences
50. A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
    Ceder, Sophia, Eriksson, Sofi E, Cheteh, Emarndeena H, Dawar, Swati, Corrales Benitez, Mariana, Bykov, Vladimir J N, Fujihara, Kenji M, Grandin, Mélodie, Li, Xiaodun, Ramm, Susanne et al. · 2021 · EMBO Molecular Medicine
51. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells
    YOSHIKAWA, NOBUHISA, KAJIYAMA, HIROAKI, NAKAMURA, KAE, UTSUMI, FUMI, NIIMI, KAORU, MITSUI, HIROKO, SEKIYA, RYUICHIRO, SUZUKI, SHIRO, SHIBATA, KIYOSUMI, CALLEN, DAVID et al. · 2016 · Oncology Reports
52. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status
    Patyka, Mariia, Sharifi, Zeinab, Petrecca, Kevin, Mansure, Jose, Jean-Claude, Bertrand, Sabri, Siham · 2016 · Oncotarget
53. The TP53 tumor suppressor gene: From molecular biology to clinical investigations
    Panagiotis Baliakas, Thierry Soussi · 2025 · Journal of Internal Medicine
54. Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer
    Georgina L. Gregory, Ian M. Copple · 2022 · Molecular Therapy — Nucleic Acids
55. Awakening the “guardian of genome”: reactivation of mutant p53
    Akshay Binayke, Sarthak Mishra, Prabhat Suman, Suman Das, Harish Chander · 2018 · Cancer Chemotherapy and Pharmacology
56. SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways
    Elisa Grassi, Valeria Vezzoli, Irene Negri, Árpád Lábadi, Laura Fugazzola, Giovanni Vitale, Luca Persani · 2015 · Oncotarget
57. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers
    S. Lindsey Davis, Sabine Eckhardt, John J. Tentler, Jennifer Robinson Diamond · 2014 · Therapeutic Advances in Medical Oncology
58. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53
    Satish Kumar Ramraj, Sugantha Priya Elayapillai, Richard C. Pelikan, Yan Daniel Zhao, Zitha Redempta Isingizwe, Amy L. Kennedy, Stanley A. Lightfoot, Doris M. Benbrook · 2019 · International Journal of Cancer
59. The p53–53BP1-Related Survival of A549 and H1299 Human Lung Cancer Cells after Multifractionated Radiotherapy Demonstrated Different Response to Additional Acute X-ray Exposure
    Margarita V. Pustovalova, Lina Alhaddad, Nadezhda M. Smetanina, A. K. Chigasova, Taisia Blokhina, Roman N. Chuprov‐Netochin, Andreyan Nikolaevich Osipov, Sergey V. Leonov · 2020 · International Journal of Molecular Sciences
60. Drug Repurposing for the Treatment of Acute Myeloid Leukemia
    Vibeke Andresen, Bjørn Tore Gjertsen · 2017 · Frontiers in Medicine
61. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition
    Monika Aggarwal, Rahul Saxena, Nasir Asif, Elizabeth Sinclair, Judy Tan, Idalia M. Cruz, Deborah L. Berry, Bhaskar Kallakury, Quynhchi Pham, Thomas T. Y. Wang et al. · 2019 · Journal of Experimental & Clinical Cancer Research
62. Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer
    Taylor P Berke, Simon H. Slight, Salman M. Hyder · 2022 · Dove Medical Press (Taylor and Francis Group)
63. Molecular Approaches to Treating Pediatric Leukemias
    Michaela Kuhlen, Jan‐Henning Klusmann, Jessica I. Hoell · 2019 · Frontiers in Pediatrics
64. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
    Jan Philipp Bewersdorf, Rory Michael Shallis, Lohith Gowda, Wei Wei, Karl M. Hager, Iris Isufi, Tae Kon Kim, Manoj M. Pillai, Stuart Seropian, Nikolai Alexandrovich Podoltsev et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
65. Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations
    Yan Jiang, Jean‐Richard Eveillard, Marie‐Anne Couturier, Benoît Soubise, Jian‐Min Chen, Sujun Gao, Audrey Basinko, Fréderic Morel, Nathalie Douet‐Guilbert, Marie‐Bérengère Troadec · 2021 · Cancers
66. Molecular pathology and prostate cancer therapeutics: from biology to bedside
    Daniel Nava Rodrigues, Lisa M. Butler, David Lorente Estelles, Johann Sebastian De Bono · 2013 · The Journal of Pathology
67. TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
    Cosimo Cumbo, Giuseppina Tota, Luisa Anelli, Antonella Zagaria, Giorgina Specchia, Francesco Albano · 2020 · International Journal of Molecular Sciences
68. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
    David Andrew Sallman · 2020 · Haematologica
69. The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
    Synnott, Naoise C., Madden, Stephen F., Bykov, Vladimir J.N., Crown, John, Wiman, Klas G., Duffy, Michael J. · 2018 · Translational Oncology
70. Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?
    Dhi Vya Lim, Wei Hwei Woo, Jing Xuan Lim, Xin Yee Loh, Hui Ting Soh, Seng Yung Adrian Lim, Zheng Yang Lee, Hui-Yin Yow, Sharina Binti Hamzah, Renukha Sellappans et al. · 2023 · Current Molecular Pharmacology
71. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations
    Garret M. K. Leung, Chunxiao Zhang, Nelson K.L. Ng, Ning Yang, Stephen S.Y. Lam, Chun Hang Au, Tsun Leung Chan, Edmond S.K. Ma, Sze Pui Tsui, Ho Wan Alvin Ip et al. · 2019 · American Journal of Hematology
72. New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
    Razan Mohty, Rama Al Hamed, Éolia Brissot, Ali A. Bazarbachi, Mohamad Mohty · 2023 · Haematologica
73. Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis
    Niall M. Corcoran, Michael J. Clarkson, Ryan Stuchbery, Christopher M. Hovens · 2016 · Clinical Cancer Research
74. JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress
    Anna Kostecka, Alicja Sznarkowska, Katarzyna Meller, Pilar Acedo, Yao Shi, Habib A. M. Sakil, Anna Kawiak, M. Lion, Aleksandra Królicka, Margareta Wilhelm et al. · 2014 · Cell Death and Disease
75. Battle Against Cancer: An Everlasting Saga of p53
    Qian Hao, William Cho · 2014 · International Journal of Molecular Sciences
76. Overview of Ferroptosis and Synthetic Lethality Strategies
    Yuko Kinowaki, Towako Taguchi, Iichiroh Onishi, Susumu Kirimura, Masanobu Kitagawa, Kouhei Yamamoto · 2021 · International Journal of Molecular Sciences
77. p53 as a potential target for treatment of cancer: A perspective on recent advancements in small molecules with structural insights and SAR studies
    Chahat, Rohit Bhatia, Bhupinder Kumar · 2022 · European Journal of Medicinal Chemistry
78. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
    Ecaterina E Ileana Dumbrava, Geoffrey Ira Shapiro, Aparna R. Parikh, Melissa Lynne Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, A. Vandross, Shivaani Kummar, Dale Randall Shepard et al. · 2026 · New England Journal of Medicine
79. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes
    David P. Steensma · 2018 · Blood
80. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation
    Teruyuki Kobayashi, Tomoki Makino, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Eiichi Morii et al. · 2021 · British Journal of Cancer
81. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia
    Julie Anne Elizabeth Irving · 2015 · British Journal of Haematology
82. Susceptibility of acute myeloid leukemia cells to ferroptosis and evasion strategies
    Hanyun Zhang, Chunjie Sun, Qi Sun, Li Ye, Chao Zhou, Changgang Sun · 2023 · Frontiers in Molecular Biosciences
83. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals
    Abrams, Stephen L., Lertpiriyapong, Kvin, Yang, Li V., Martelli, Alberto M., Cocco, Lucio, Ratti, Stefano, Falasca, Marco, Murata, Ramiro M., Rosalen, Pedro L., Lombardi, Paolo et al. · 2018 · Advances in Biological Regulation
84. Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells
    Wei Zhang, Bin Yi, Chao Wang, Dongquan Chen, Sejong Bae, Shi Wei, Rongjun Guo, Changming Lu, Lisa L.H. Nguyen, Wei‐Hsiung Yang et al. · 2015 · Clinical Cancer Research
85. SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade
    Virginia Olivia Volpe, Guillermo Garcia‐Manero, Rami S. Komrokji · 2021 · Clinical Lymphoma Myeloma & Leukemia
86. Gene regulatory mechanisms orchestrated by p63 in epithelial development and related disorders
    Evelyn N. Kouwenhoven, Hans van Bokhoven, Huiqing Zhou · 2015 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
87. Insights into the Effect of the G245S Single Point Mutation on the Structure of p53 and the Binding of the Protein to DNA
    Marco Gaetano Lepre, Sara Ibrahim Omar, Gianvito Grasso, Umberto Morbiducci, Marco A. Deriu, Jack A. Tuszyński · 2017 · Molecules
88. Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
    Steven Daniel Green, Heiko Koenig · 2020 · Frontiers in Genetics
89. miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc
    Manujendra N. Saha, Jahangir Abdi, Yijun Yang, Hong Chang · 2016 · Oncotarget
90. PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53
    Debora Russo, Laura Ottaggio, Giorgia Foggetti, Matilde Masini, Pellegrino Masiello, Gilberto Fronza, Paola Menichini · 2013 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
91. Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies
    Jolanda Magri, Alessandro Gasparetto, Laura Conti, Enzo Calautti, Chiara Cossu, Roberto Ruiu, Giuseppina Barutello, Federica Cavallo · 2021 · Cells
92. CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
    Ashwini Makhale, Devathri M. Nanayakkara, Prahlad V. Raninga, Kum Kum Khanna, Murugan Kalimutho · 2021 · International Journal of Molecular Sciences
93. p63 in corneal and epidermal differentiation
    Flavia Novelli, Carlo Ganini, Gerry Melino, Carlo Nucci, Yuyi Han, Yufang Shi, Ying Wang, Eleonora Candi · 2022 · Biochemical and Biophysical Research Communications
94. The p53-Reactivating Small Molecule RITA Induces Senescence in Head and Neck Cancer Cells
    Hui‐Ching Chuang, Liang Peng Yang, Alison L. Fitzgerald, Abdullah A. Osman, Sang Hyeok Woo, Jeffrey N. Myers, Heath Devin Skinner · 2014 · PLoS ONE
95. Genomic landscape of gastric cancer: molecular classification and potential targets
    Jiawei Guo, Weiwei Yu, Hui Su, Xiufeng Pang · 2016 · Science China Life Sciences
96. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
    Phaik Ju Teoh, Chonglei Bi, Chirackal Sintosebastian, Liang Seah Tay, Rafaël Fonseca, Wee Joo Chng · 2016 · Oncotarget
97. Near-Comprehensive Resequencing of Cancer-Associated Genes in Surgically Resected Metastatic Liver Tumors of Gastric Cancer
    Naoki Ikari, Akiko Serizawa, Shohei Mitani, Masakazu Yamamoto, Toru Furukawa · 2019 · American Journal Of Pathology
98. Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
    Adam McLain Kase, John Alton Copland, Winston W. Tan · 2020 · OncoTargets and Therapy
99. An integrated view of p53 dynamics, function, and reactivation
    Özlem Demir, Emilia Pecora de Barros, Tavina L. Offutt, Mia A. Rosenfeld, Rommie E. Amaro · 2021 · Current Opinion in Structural Biology
100. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53
     Mona Sobhani, Jahangir Abdi, Manujendra N. Saha, Christine Chen, Hong Chang · 2015 · Cancer Biology & Therapy